SCHEMBL3608744

SCHEMBL3608744

CCOC(=O)c1oc2ccc(CO[SiH](C)C)c(C(C)(C)C)c2c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.51
RAB9A P51151 3/20 0.49
NPC1 O15118 2/20 0.49
MAPT P10636 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
HSD17B10 Q99714 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
NMT2 O60551 7/20 0.44
NMT1 P30419 7/20 0.44
ADRB2 P07550 3/20 0.43
ADRB1 P08588 3/20 0.43
ADRB3 P13945 3/20 0.43
ALDH1A1 P00352 3/20 0.42
HIF1A Q16665 1/20 0.41
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3620532 0.87 EDNRA (0.43) KDM4ERAB9ANPC1MAPTL3MBTL1
SCHEMBL3608031 0.77 RAB9A (0.65) KDM4ERAB9ANPC1MAPTL3MBTL1
SCHEMBL10741846 0.74 RAB9A (0.60) KDM4ERAB9ANPC1MAPTL3MBTL1
SCHEMBL9868567 0.73 RAB9A (0.59) KDM4ERAB9ANPC1MAPTL3MBTL1
SCHEMBL10743101 0.72 RAB9A (0.62) KDM4ERAB9ANPC1MAPTL3MBTL1
SCHEMBL10738818 0.71 RAB9A (0.60) KDM4ERAB9ANPC1MAPTL3MBTL1
SCHEMBL3622124 0.71 RAB9A (0.57) KDM4ERAB9ANPC1MAPTL3MBTL1
SCHEMBL10738743 0.70 RAB9A (0.55) KDM4ERAB9ANPC1MAPTL3MBTL1
SCHEMBL3608516 0.70 RAB9A (0.70) KDM4ERAB9ANPC1MAPTL3MBTL1
SCHEMBL10739314 0.69 RAB9A (0.58) KDM4ERAB9ANPC1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same WYETH (US) 2010-06-03 US disclosed
EP-1692124-B1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH CORP (US) 2008-10-15 EP disclosed
US-7420001-B2 Biaryl sulfonamides and methods for using same WYETH (US) 2008-09-02 US disclosed
EP-1692124-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS Wyeth (US) 2006-08-23 EP disclosed
WO-2005061477-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH (US) 2005-07-07 WO disclosed
US-20050143422-A1 Biaryl sulfonamides and methods for using same WYETH (US) 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same STS, MMP3, AADAC KDM4E 1421/4885RAB9A 3864/4885NPC1 2605/4885
US-20050143422-A1 Biaryl sulfonamides and methods for using same STS, MMP3, AADAC KDM4E 1421/4885RAB9A 3864/4885NPC1 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.